-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 18th, Sansheng Guojian issued an announcement stating that the company's SSGJ-706 treatment of advanced solid tumors, relapsed or refractory lymphomas has been approved by the US FDA to enter Phase I/II clinical studies
.
SSGJ-706 is a recombinant bispecific antibody developed by Sansheng Guojian with independent intellectual property rights (bispecific antibody platform)
.
The antibody simultaneously binds to PD1 and another target closely related to tumor immunosuppressive function, thereby more effectively promoting T cell activation and proliferation, and further enhancing its tumor killing activity